IRLA IRLA · Stock Open IRLA in new tab
Analyst price targets
Recent rating changes, newest first
IRLA Analysis (IRLA)
Is IRLA a good investment? IRLA (IRLA) is currently trading at 31.67 USD. Market analysts have a consensus price target of 75.00 USD. This suggests a potential upside from current levels.
Earnings Schedule: IRLA is expected to release its next earnings report on Nov. 11, 2026. The market consensus estimate for Forward EPS is -4.68.
Investor FAQ
Does IRLA pay a dividend?
No, it does not currently pay a dividend.
What asset class is IRLA?
IRLA is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 11, 2026. The company currently has a trailing EPS of -214.01.
Company Profile
IRulya Therapeutics Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidate comprises eDSP, which is in Phase 3 for the treatment of rare pediatric neurodegenerative diseases, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene. Its AIDE technology platform is a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells and consists of automated equipment, the RCL, a sterile single-use consumable treatment kit comprising medical device kits, syringe kits, and process solutions. IRulya Therapeutics Inc. was formerly known as Quince Therapeutics, Inc. and changed its name to IRulya Therapeutics Inc. in October 2026. The company was incorporated in 2012 and is headquartered in New Haven, Connecticut.
| Split Date | Split Ratio to 1 |
|---|---|
| April 13, 2026 | 1:10 |
| June 30, 2026 | 1:20 |
Community Discussion